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Abstract
Background: Second-generation drug-eluting stents (DES) have raised the bar of clinical performance. These stents are
mostly made from cobalt chromium alloy. A newer generation DES has been developed from platinum chromium
alloy, but clinical data regarding the efficacy and safety of the platinum chromium-based everolimus-eluting stent (PtCr-
EES) is limited, with no comparison data against the cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES). In
addition, an antiplatelet regimen is an integral component of medical therapy after percutaneous coronary intervention
(PCI). A 1-week duration of doubling the dose of clopidogrel (double-dose antiplatelet therapy (DDAT)) was shown to
improve outcome at 1 month compared with conventional dose in acute coronary syndrome (ACS) patients
undergoing PCI. However in Asia, including Korea, the addition of cilostazol (triplet antiplatelet therapy (TAT)) is used
more commonly than doubling the dose of clopidogrel in high-risk patients.
Methods: In the ‘Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS
of drug-elUting stents & antiplatelet REgimen’ (HOST-ASSURE) trial, approximately 3,750 patients are being
prospectively and randomly assigned in a 2 × 2 factorial design according to the type of stent (PtCr-EES vs CoCr-
ZES) and antiplatelet regimen (TAT vs DDAT). The first primary endpoint is target lesion failure at 1 year for the
stent comparison, and the second primary endpoint is net clinical outcome at 1 month for comparison of
antiplatelet therapy regimen.
Discussion: The HOST-ASSURE trial is the largest study yet performed to directly compare the efficacy and safety
of the PtCr-EES versus CoCr-ZES in an ‘all-comers’ population. In addition, this study will also compare the clinical
outcome of TAT versus DDAT for 1-month post PCI.
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Background
Various second-generation drug-eluting stents (DES) have
been developed in the hopes of improving both efficacy
and safety compared with first-generation DES. Cumula-
tive evidence is building suggesting that compared with
the paclitaxel-eluting stent, the second-generation everoli-
mus-eluting stent (EES; Xience V, Abbott Vascular, Santa
Clara, CA, USA, Promus, Boston Scientific, Natick, MA,
USA) is more effective and safe [1-3], and compared with
the sirolimus-eluting stent, it has similar efficacy with a
trend toward better safety [4-6]. The next addition to the
second-generation DES market has been the zotarolimus-
eluting stent (ZES; Resolute, Medtronic, Minneapolis, MN,
USA), which showed equivalent outcome compared with
the EES in the RESOLUTE All-Comers randomized trial
[7]. Both EES and ZES are based on a cobalt chromium
alloy stent. Most recently, a newly developed stent alloy,
the platinum chromium alloy, was incorporated with ever-
olimus to create the platinum chromium-based EES
(PtCr-EES), the Promus Element stent (Boston Scientific,
Natick, MA, USA). There are limited data on the clinical
efficacy and safety of the PtCr-EES with only one modestly
sized randomized trial that compared it against the cobalt
chromium-based EES in a select group of patients and
lesions [8]. In the current study, the PtCr-EES will be
compared against the cobalt chromium-based ZES (CoCr-
ZES) in a larger scale study with a broader all-comers
population.
In addition, antiplatelet regimen is an integral compo-
nent of medical therapy after percutaneous coronary inter-
vention (PCI). In particular, inhibition of platelet reactivity
in the first month post PCI is known to be critical in pre-
venting thrombotic events, since higher on-treatment pla-
telet reactivity is reported to be associated with higher risk
of hard endpoints [9-12]. In the CURRENT-OASIS 7 trial,
a 1-week duration of doubling the dose of clopidogrel was
shown to improve outcome at 1 month compared with
conventional dose in acute coronary syndrome (ACS)
patients undergoing PCI [13]. In Asia including Korea, the
addition of cilostazol as a third antiplatelet agent is used
more commonly than doubling the dose of clopidogrel in
high-risk patients. However, there has been no large-scale
comparison of triple antiplatelet therapy (TAT) versus
double-dose clopidogrel antiplatelet therapy (DDAT) to
date.
Methods
Study objectives and hypotheses
The primary objective of the present study is to compare
the efficacy and safety of coronary stenting with the
PtCr-EES compared with the CoCr-ZES in the treatment
of coronary stenosis, and to evaluate the efficacy and
safety of a 1 month duration of TAT consisting of
aspirin, clopidogrel 75 mg, and cilostazol 200 mg versus
DDAT consisting of aspirin and clopidogrel 150 mg. The
working hypothesis of this trial is that PtCr-EES is non-
inferior to CoCr-ZES in prevention of target lesion failure
(TLF) at 1-year post PCI, and TAT is non-inferior to
DDAT regarding net clinical outcome, defined as a com-
posite of cardiac death, non-fatal myocardial infarction
(MI), stent thrombosis, stroke and PLATO (’PLATelet
inhibition and patient Outcomes’) major bleeding at 1
month [14].
Study design
This is a prospective, randomized, single blind, blinded
endpoint evaluation, multicenter trial with a 2 × 2 factorial
design. The study algorithm is shown in Figure 1. After
enrollment and index PCI procedure, clinical follow-up
will occur at 1, 3, 12 months and yearly up to 3 years after
intervention. Follow-ups will be conducted as telephone
contacts or office visits. Unless clinically necessary, there
will be no angiographic follow-up until 12 months post
PCI, the timepoint for the primary endpoint of the stent
comparison. In a subset of patients angiographic follow-up
will be recommended at 13 months post PCI. In another
subgroup of patients, clopidogrel on-treatment platelet
reactivity will be measured using the VerifyNow P2Y12
assay at baseline PCI and at 1-month follow-up. This
study is an investigator-initiated clinical trial with grant
support from two sources, the Ministry of Health, Welfare,
and Family Affairs of the Republic of Korea, and Boston
Scientific Korea. Other than providing financial support,
Boston Scientific was not involved with the protocol devel-
opment or the study process, including site selection,
management, and data collection and analysis. The
authors are solely responsible for the design and conduct
of this study, all study analyses, the drafting and editing of
the paper and its final contents.
Study population
Patients that are at least 18 years of age who show on cor-
onary angiogram to have significant coronary artery or
graft stenosis and meet all of the inclusion and exclusion
criteria (Additional file 1: Table S1) are eligible for this
study. This will be an ‘all-comers’ study, with no angio-
graphic exclusion criteria in order to mimic real world
clinical practice and will include the likes of multivessel
stenting, left main stenting, chronic total occlusion inter-
vention, bifurcation stenting, saphenous vein graft stent-
ing, previous stent restenosis, and so on. The major
exclusion criteria for study enrollment will be known
hypersensitivity or contraindication to heparin, aspirin,
clopidogrel, cilostazol, everolimus, zotarolimus, or contrast
media, systemic (intravenous) us of everolimus or zotaroli-
mus within 12 months, females of childbearing potential,
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unless a recent pregnancy test is negative, a history of
bleeding diathesis, known coagulopathy (including
heparin-induced thrombocytopenia), abnormal hemogram
(hemoglobin < 10 g/dl or platelet count < 100,000 cells/μl)
or will refuse blood transfusions, patients with severe
left ventricular systolic dysfunction (left ventricular ejec-
tion fraction < 25%), those with cardiogenic shock,
gastrointestinal or genitourinary bleeding within the prior
3 months, or major surgery within 2 months, and sympto-
matic heart failure. The patients that agree to participate in
the study and give written informed consent, will be rando-
mized 2:1 to either (a) PtCr-EES or (b) CoCr-ZES, and 1:1
to either (a) TAT or (b) DDAT (2 × 2 design). A total of
3,750 patients plan to be enrolled from 40 high-volume
All comers with symptomatic coronary artery disease or coronary artery stenosis > 70% by 
visual estimation receiving percutaneous coronary intervention 
Eligibility screened [Table 1]
Net clinical outcome at 1 month post-PCI (ITT)
Aspirin (300mg) + Clopidogrel (300~600mg) p.o.
Informed Consent 
Platinum-chromium based 
everolimus-eluting stent
N = 2500
200mg Cilostazol loading
N = 1875
No Cilostazol loading
N = 1875
Cobalt-chromium based
zotarolimus-eluting stent
N = 1250
VerifyNow® ASA & VerifyNow® P2Y12 after 12~24 hours post-PCI
Cumulative TLR at 12 months post-PCI (ITT)
100mg ASA, 75mg Clopidogrel
100mg Aspirin QD
75mg Clopidogrel QD
100mg Cilostazol BID
100mg Aspirin QD
150mg Clopidogrel QD
- Anti-PLT arm
- Stent arm
Patient
RANDOMIZATION
Figure 1 Study algorithm.
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hospitals in Korea, the names and investigators of which
are listed in Additional file 2: Appendix A.
Interventions and study device, drug
PCI will be performed with the standard technique and
device, that is, catheter, guidewire and balloon catheter.
The decision to predilate the lesion, use glycoprotein IIb/
IIIa inhibitors and dilate the stent adjunctively will be up
to the operator’s discretion. The Promus Element stent is
available in diameters of 2.25, 2.5, 2.75, 3.0, 3.5 and 4.0
with lengths of 8, 12, 16, 20, 24, 28, 32, and 38 mm (32
and 38 mm lengths not available for 2.25 and 2.5 mm dia-
meters). The Endeavor Resolute stent is available in dia-
meters of 2.5, 2.75, 3.0, 3.5 and 4.0, with lengths of 12, 15,
18, 24, 30 and 38 mm (except for 2.5 mm stents which are
available as 14 mm length instead of 15 mm, and 38 mm
lengths not available for 2.5 and 2.75 mm diameters). It
will be recommended that all diseased coronary or graft
lesions that are the targets of intervention be fully covered
by the stent, with non-diseased tissue at each end of the
stent. In cases of long lesions that cannot be fully covered
by one stent, stent overlap of approximately 1 mm to 4
mm will be recommended per manufacturer’s instruction
for use (IFU). It will be recommended that the allocated
stent be implanted in all lesions treated in the same
patient. However, other stents may be used in case of
device failure, or situations where the operator decides
that it is in the best interest of the patient to do so. The
use of intravascular ultrasound (IVUS) or optical coher-
ence tomography (OCT) to guide in the procedure will
also be up to the operator’s discretion.
All patients will receive approximately 300 to 600 mg of
clopidogrel and 300 mg of aspirin loading before the pro-
cedure. The patients randomized to the TAT group will
receive an additional loading of 200 mg cilostazol (Otsuka,
Korea) followed by 100 mg twice a day maintenance.
Those randomized to the DDAT group will receive
150 mg of clopidogrel maintenance.
Outcome measures
There are two primary endpoints in this study. The pri-
mary endpoint of the trial for the stent comparison will be
TLF, defined as a composite of cardiac death, target ves-
sel-related non-fatal MI and ischemia-driven target lesion
revascularization (TLR) at 12 months. The primary end-
point for the antiplatelet regimen comparison will be net
clinical outcome, defined as a composite of cardiac death,
non-fatal MI, stent thrombosis, stroke and PLATO major
bleeding at 1 month [14]. The individual component defi-
nitions appear in Additional file 2: Appendix B. Stent
thrombosis will be adjudicated according to the definitions
of the Academic Research Consortium [15]. All endpoints
will be analyzed principally on an intention-to-treat basis.
Secondary endpoints of the study will include all of the
individual components of the primary endpoint. In addi-
tion, all death, ischemia-driven target vessel revasculariza-
tion (TVR), target vessel failure (TVF), acute success
(device, procedure) will be included as secondary end-
points. In the subgroup of patients that receive 13-month
angiographic follow-up, both stents will also be analyzed
using quantitative coronary angiography (QCA) for late
luminal loss, percentage diameter stenosis, IVUS for
percentage neointimal volume, or OCT for percentage
neointimal coverage. In another subgroup of patients with
on-treatment platelet reactivity (OPR) measurement, OPR
will be compared between the two antiplatelet regimens,
and according to genotype status. The effect of OPR on
clinical outcome will also be analyzed.
Statistical considerations
Sample size calculations
To test the first hypothesis that the PtCr-EES is non-infer-
ior to CoCr-ZES in reducing 12-month cumulative TLF
after PCI, we assumed the TLF rate of PtCr-EES and
CoCr-ZES to be 6.5%, based on the results from previous
randomized trials [1,2,7]. Using a non-inferiority log-rank
design with a non-inferiority margin of hazard ratio 1.5,
sampling ratio of EES:ZES at 2:1, allowing 5% attrition rate
for the 12 months, a total of 3,750 patients would result in
a power of at least 80% power with an one-sided a of
2.5%.
Also, to test the second hypothesis that TAT is non-
inferior to DDAT regarding 1-month net clinical outcome,
we assumed the net clinical outcome rate of TAT and
DDAT to be 2.0% and 3.0%, respectively. The net clinical
outcome is defined as a composite of cardiac death, non-
fatal MI, stent thrombosis, stroke and PLATO major
bleeding at 1 month. With a non-inferiority design, a non-
inferiority margin of 0.75%, 1:1 randomization to either
groups and allowing for 2.5% attrition for 1-month clinical
follow-up, a total of 3,750 patients would provide a one-
sided a of 2.5% and > 90% power.
Statistical analyses
All primary and secondary endpoints will be analyzed on
an intention-to-treat basis (all patients analyzed as part of
their assigned treatment group). The endpoints will also
be analyzed both on a per-patient and per-lesion basis,
whenever applicable. For patients receiving multivessel
PCI, the index lesion analyzed in the per-patient analysis
will be determined randomly by a computer prior to QCA
analysis. For intent-to-treat analysis, all patients who
signed the written informed consent form and are rando-
mized in the study will be included in the analysis sample,
regardless of whether or not the correct treatment was
administered, or whether crossover occurred.
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The second primary endpoint of 12-month cumulative
TLF and 1-month cumulative net clinical outcome will be
analyzed by comparing the Kaplan-Meier event rates using
the log rank test on an intention-to-treat basis. The null
hypothesis will be evaluated using a non-inferiority statis-
tics. The outcomes will also be analyzed according to sub-
groups defined a priori. These include the following: for
comparison of the stent arm, subgroup analysis will be per-
formed according to the lesion length, vessel size, renal
dysfunction, multivessel stenting, and presence or absence
of diabetes mellitus; for comparison of the antiplatelet arm,
subgroup analysis will be performed according to the pre-
scription status of calcium-channel blockers, 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-
tors, allocated stent, renal dysfunction, multivessel stenting,
and the presence or absence of diabetes mellitus. The mul-
tiple imputation method will be used to handle missing
data.
Trial organization and ethical considerations
The overall trial organization is summarized in Additional
file 2: Appendix C. The trial was designed by the principal
investigators and the executive committee. Besides the
executive committee, the steering committee, data safety
monitoring board, and the clinical event adjudication com-
mittee will be involved in the execution, administration,
and supervision of the trial. The specific role and informa-
tion regarding each of the committees appear in Additional
file 2: Appendix C. The study will be sponsored by the
Seoul National University Hospital (SNUH) Cardiovascular
Clinical Research Center (CCRC) and the data will be man-
aged by an independent contract research organization,
Dream CIS Inc. Dream CIS will be responsible for the
development of a web-based randomization system, main-
tenance of the web-based case report form, and data collec-
tion from individual sites. Site monitoring will be
performed by the CCRC of SNUH. The trial monitors will
review the documents of at least 30% of the patients
enrolled from each participating center, at appropriate
intervals, for accuracy and completeness and to ensure
compliance with the protocol. The trial monitor will be
able to inspect all documents and required records that are
maintained by the individual investigator and site, including
medical records (office, clinic, or hospital) for the subjects
in this trial. The study will be performed in accordance
with the Declaration of Helsinki. Before participation of the
study, each patient will be given full information, that is,
purpose, methods, rights, duties and possible risk/benefits
of the study in plain, lay language. Written, informed con-
sent is a prerequisite to the participation in the study.
Ethical approval
This study was approved by the institutional review board
at Seoul National University Hospital (D-1005-001-068)
and by the local ethical committee at each participating
hospital. The protocol of the trial has been registered at
http://www.clinicaltrials.gov (NCT01267734).
Discussion
EES and ZES in clinical practice
The second-generation CoCr-EES (Xience V, Promus) has
been shown to be either comparable or better than its
first-generation counterparts. In large scale randomized
trials against paclitaxel-eluting stents (PES), such as the
SPIRIT IV and COMPARE trials, it was superior to PES
with regard to both efficacy and safety where the primary
clinical endpoints were reduced by 38% and 31%, respec-
tively [1,2], which has now been reaffirmed in a meta-ana-
lysis [16]. In randomized trials and meta-analysis
comparing CoCr-EES and SES, such as the EXCELLENT,
ISAR-TEST 4, SORT-OUT IV, and so on, CoCr-EES
showed similar efficacy with slight trend toward superior
safety [4-6]. The next addition to the second-generation
DES market has been the CoCr-ZES (Endeavor Resolute),
which showed equivalent outcome compared with the
CoCr-EES in the RESOLUTE All-Comers randomized
trial [7]. Because of the all-comers population that was
studied in this trial, data were available regarding to the
performance of the second-generation stents in complex
lesions such as coronary total occlusions, bifurcation
lesions, saphenous vein grafts, in-stent restenosis, unpro-
tected left main lesions, multivessel stenting, and so on,
which constituted approximately two-thirds of the lesions
treated in the trial [17]. In this complex subgroup, there
were no significant differences between the two DES
devices but the TLF rate at 1 year numerically favored
CoCr-ZES. Both of these second-generation DES are
based on a cobalt chromium alloy stent. Most recently, a
newly developed stent alloy, the platinum chromium alloy,
was incorporated with everolimus to create the PtCr-EES,
the Promus Element stent (Boston Scientific). In the only
randomized trial to date with the PtCr-EES, the PLATI-
NUM trial, where it was compared against CoCr-EES in a
select group of patients with various angiographic exclu-
sions [8], PtCr-EES was non-inferior to CoCr-EES for the
primary endpoint of TLF, with insignificant differences in
measures of safety and efficacy through 1 year. Both stents
showed low event rates at 1 year (TLF rate: 3.4% vs 2.9%
for PtCr-EES vs CoCr-EES, P = 0.60). However the PtCr-
EES has not been studied randomly in a broader popula-
tion of patients as was enrolled in the RESOLUTE
All-Comers trial, which better reflects the day-to-day clini-
cal practice in most centers of coronary intervention. The
non-inferiority margin of 3.25% may seem large given that
the estimated rate of the primary endpoint is 6.5%. How-
ever, in the RESOLUTE All-Comers trial and the PLATI-
NUM trial, well known previous studies incorporating
the non-inferiority design regarding stent comparisons, a
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non-inferiority margin of 3.5% has been used [7,8]. In
addition, because of the paucity of the data on PtCr-EES,
the sampling ratio was set at 2:1 to maximize the number
of patients randomized to the PtCr-EES arm.
Antiplatelet regimen after PCI
Antiplatelet therapy is one of the most important compo-
nents of successful outcome after PCI. High on-treatment
platelet reactivity (HOPR) has been shown to be an inde-
pendent predictor of thrombotic outcomes [9-12]. In par-
ticular, the first month after PCI is the most important
period to inhibit platelet function to prevent thrombotic
events, since the greatest association between heightened
platelet reactivity and thrombotic outcome is seen in the
first month post PCI [18]. In Korea, where the HOPR rate
of the general population receiving PCI is above 50% and
frequency of the cytochrome P450 2C19 (CYP2C19) loss-
of-function (LOF) allele is greater than 60% [12,19-21], we
may need increased platelet inhibition during this critical
period.
To increase platelet inhibition after PCI, the approach is
slightly different between Western and Asian doctors.
Before prasugrel and ticagrelor, most Western doctors
prescribed double dose of clopidogrel in high-risk settings.
However, in Asia and in particular in Korea, doctors prefer
addition of cilostazol on conventional dual antiplatelet
therapy (DAPT) to doubling the dose of clopidogrel. In
the CURRENT-OASIS 7 trial, a 1-week duration of dou-
bling the dose of clopidogrel was shown to improve out-
come at 1 month compared with conventional dose in
ACS patients undergoing PCI [13]. The basis of adding
cilostazol in Korea comes from pharmacodynamic studies
from our group and others, which have shown that TAT
is superior to DDAT with regard to inhibition of platelet
reactivity in patients with high platelet reactivity [22], and
in carriers of the CYP2C19 LOF allele [23]. In the
DECLARE-Diabetes, and DECLARE-Long studies, TAT
was superior to conventional DAPT regarding inhibition
of neointima formation and significantly reduced rates of
clinically driven TLR [24,25]. In the CILON-T trial, which
was underpowered to show differences in clinical out-
come, there were no significant difference between TAT
and conventional DAPT although TAT more profoundly
reduced OPR [26]. However in the post hoc analysis, we
showed that there was a significant trend toward worse
outcome in those with high OPR suggesting that cilostazol
may have some beneficial effects in higher-risk
populations.
Because of the paucity of sound clinical data regarding
the use of TAT based on randomized clinical trials, and
in light of the abundant use of cilostazol as a third agent
in post-PCI management in Korea, a large scale rando-
mized controlled trial (RCT) to confirm the safety and
efficacy of TAT is needed at present. After initiation of
the ‘Harmonizing Optimal Strategy for Treatment of cor-
onary artery stenosis - sAfety & effectiveneSS of drug-
elUting stents & antiplatelet REgimen’ (HOST-ASSURE)
trial, we anticipate enrollment within 1 year. The large
scale and all-comers design of the HOST-ASSURE trial
will provide important insight into two issues in interven-
tional cardiology. First, it will test whether the newest
DES platform, PtCr-EES will be as effective and safe as
CoCr-ZES in preventing TLF. Second, it will also address
the issue of whether TAT is non-inferior to DDAT in
reducing net clinical outcome within the first month post
PCI.
Trial status
The HOST-ASSURE Trial is ongoing. Patient recruit-
ment has been completed and follow-up is being
conducted.
Additional material
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